Apr. 19 at 5:38 PM
$ZLAB Zai Lab presents new preclinical data on ZL-1503
Zai Lab Limited announced new data from a preclinical study of ZL-1503, demonstrating that the company's internally developed IL-13/IL-31Ralpha bispecific antibody may lead to sustained suppression of intense pruritus and inflammation caused by atopic diseases. The findings, featured in a poster presentation at the IMMUNOLOGY2026 conference in Boston, MA, reinforce the potential of ZL-1503 to be a first-in-class treatment option for moderate-to-severe atopic dermatitis and other IL-13 and IL-31-driven diseases.
"The breadth of activity across pruritus and atopic disease models in this study, including sustained suppression of symptoms from a single dose over 112 days, reinforces our belief that dual targeting of IL-13 and IL-31 pathways represents a compelling therapeutic approach," said Rafael G. Amado, M.D., President, Head of Global Research and Development at Zai Lab. "These data support our conviction that ZL-1503 has the potential to make a meaningful difference for patients and collectively support its clinical advancement."
